Yazarlar : Chevallier P, Pigneux A, Robillard N, Ayari S, Guillaume T, Delaunay J, Eveillard M, Dumas PY, Lippert E, Mohty M, Leguay T.

Yayın : Leuk Res.

Yayın Yılı : 2011

Pubmed Linki : http://www.ncbi.nlm.nih.gov/pubmed/22172463

Konu : Lösemi

Literatür İçeriği :  

Abstract

No series have reported the results of the use of the therapeutic anti-CD20 monoclonal antibody (Rituximab) in the setting of adult refractory/relapsed B-ALL. We report here the outcomes of such nine patients treated at two french institutions by a combination of Rituximab+chemotherapy. We showed that four patients could achieve complete response while four other patients were documented with blast clearance superior to 50% from the baseline in bone marrow. We conclude that our results suggested some efficacy for the use of Rituximab in combination with chemotherapy in the setting of refractory/relapsed adult B-ALL. Larger series within prospective trials are needed to confirm these results.

Literatür Arşivi